Shanghai Zhimeng Biopharma, Inc.

This study follows patients for up to two years to check the long-term safety and effectiveness of an experimental epilepsy drug called CB03-154. It includes 144 people with focal epilepsy who successfully finished an earlier trial. The goal is to see how well the drug controls s…